• Explore /
  • Poster
  • / A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.

A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.

Abstract Poster

Authors

null

Jin Won Kim

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seognnam, South Korea

Jin Won Kim , Koung Jin Suh , Ji-Won Kim , Jin Hyun Park , Ki Hwan Kim , Yu Jung Kim , Jin-Soo Kim , Jee Hyun Kim , In Sil Choi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03464968

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4603)

DOI

10.1200/JCO.2020.38.15_suppl.4603

Abstract #

4603

Poster Bd #

211

Abstract Disclosures

Similar Posters

First Author: Nai-Jung Chiang

First Author: Shintaro Nakano

First Author: Dong Ho Lee

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.

A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.

First Author: Olivia Aranha